Compound index

Incretin & Metabolic Receptor Agonists

Retatrutide

Also known as LY3437943

Late-stage human trialsInvestigational

Last reviewed: 2026-11-19

Evidence status & limitations

Phase 2 and later human trials investigate metabolic endpoints; they do not by themselves constitute regulatory approval.

Regulatory status

No FDA-approved human medicine for this exact identity was established in this review. Investigational research is not approval.

    Status as of 2026-11-19. Regulations change. Check FDA.gov for current information.

    WADA prohibited status: current list and context

    Known risks & open questions

    Gastrointestinal symptoms and increased heart rate occurred in trials; long-term and rare risks require follow-up.

    Key sources

    Identity and editorial screen completed November 19, 2026. Previously checked primary references retained; this is not an exhaustive clinical review.

    Related compounds

    • Semaglutide

      Same scientific class · A 31-amino-acid chain. · FDA-approved for specific indications

    • Tirzepatide

      Same scientific class · A 39-amino-acid chain. · FDA-approved for specific indications

    Related glossary terms